| Cisplatin |
NCT03639168 |
Recruiting |
Phase 2 |
Chidamide Combined With Cisplatin in Head and Neck Adenoid Cystic Carcinoma (HNACC) |
Adenoid Cystic Carcinomas|Cisplatin |
https://ClinicalTrials.gov/show/NCT03639168 |
| Cisplatin |
NCT01611727 |
Completed |
Phase 2 |
Open-Label,Non-Randomized Trial of Cisplatin Chemotherapy in BRCA1-Positive Metastatic Breast Cancer Patients |
BRCA1 Mutation|Metastatic Breast Cancer |
https://ClinicalTrials.gov/show/NCT01611727 |
| Cisplatin |
NCT02994069 |
Recruiting |
Phase 2 |
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers |
Carcinoma, Squamous Cell|Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT02994069 |
| Cisplatin |
NCT02277184 |
Terminated |
Phase 1 |
Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma |
Carcinoma, Squamous Cell of Head and Neck |
https://ClinicalTrials.gov/show/NCT02277184 |
| Cisplatin |
NCT01644994 |
Recruiting |
Phase 1|Phase 2 |
Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma |
Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT01644994 |
| Cisplatin |
NCT02250872 |
Unknown status |
Phase 2|Phase 3 |
Effects of DPP4 Inhibitor on Cisplatin Induced Acute Kidney Injury |
Cancer|Cisplatin Adverse Reaction |
https://ClinicalTrials.gov/show/NCT02250872 |
| Cisplatin |
NCT01561586 |
Recruiting |
Phase 3 |
Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer |
Cervical Cancer |
https://ClinicalTrials.gov/show/NCT01561586 |
| Cisplatin |
NCT03330249 |
Active, not recruiting |
Phase 2 |
Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion |
Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT03330249 |
| Cisplatin |
NCT01928680 |
Unknown status |
Phase 2 |
Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer |
Metastatic Breast Cancer |
https://ClinicalTrials.gov/show/NCT01928680 |
| Cisplatin |
NCT03919552 |
Recruiting |
Phase 3 |
Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma |
Cisplatin|Carboplatin|NPC |
https://ClinicalTrials.gov/show/NCT03919552 |
| Cisplatin |
NCT02475772 |
Completed |
Phase 1 |
A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis |
Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT02475772 |
| Cisplatin |
NCT01674842 |
Active, not recruiting |
Phase 1 |
Cisplatin + RT for Triple Negative Breast Cancer |
Breast Cancer |
https://ClinicalTrials.gov/show/NCT01674842 |
| Cisplatin |
NCT00916500 |
Completed |
Phase 2 |
Concurrent Chemoradiation With Cisplatin Every 3 Week in Advanced Cervical Cancer |
CERVICAL NEOPLASMS |
https://ClinicalTrials.gov/show/NCT00916500 |
| Cisplatin |
NCT03644589 |
Withdrawn |
Phase 2 |
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer |
Estrogen Receptor Negative|HER2/Neu Negative|Metastatic Breast Cancer|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03644589 |
| Cisplatin |
NCT02030574 |
Terminated |
Phase 2 |
Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin |
Invasive Bladder Cancer|Bladder Cancer |
https://ClinicalTrials.gov/show/NCT02030574 |
| Cisplatin |
NCT00901537 |
Terminated |
Phase 1 |
Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer |
Non-small Cell Lung Cancer|Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT00901537 |
| Cisplatin |
NCT03558087 |
Recruiting |
Phase 2 |
Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing |
Bladder Cancer |
https://ClinicalTrials.gov/show/NCT03558087 |
| Cisplatin |
NCT03639467 |
Recruiting |
Phase 1|Phase 2 |
Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma |
Recurrent Nasopharyngeal Carcinoma|Metastatic Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03639467 |
| Cisplatin |
NCT00995761 |
Completed |
Phase 2 |
Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC) |
Non-small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT00995761 |
| Cisplatin |
NCT01165385 |
Completed |
Phase 1 |
Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors |
Solid Tumors|Metastatic Cancer |
https://ClinicalTrials.gov/show/NCT01165385 |
| Cisplatin |
NCT01114958 |
Completed |
Phase 1 |
Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases |
Lung Neoplasms|Neoplasm Metastasis |
https://ClinicalTrials.gov/show/NCT01114958 |
| Cisplatin |
NCT01149798 |
Completed |
Phase 2 |
A Combination of Abraxane and Cisplatin in Metastatic Breast Cancer |
Metastatic Breast Cancer |
https://ClinicalTrials.gov/show/NCT01149798 |
| Cisplatin |
NCT04060459 |
Recruiting |
Phase 2 |
Paclitaxel-binding Albumin and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer |
Bladder Cancer |
https://ClinicalTrials.gov/show/NCT04060459 |
| Cisplatin |
NCT01980667 |
Completed |
Phase 1 |
Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors |
Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT01980667 |
| Cisplatin |
NCT01387399 |
Unknown status |
Phase 1 |
Safety and Pharmacokinetics of Intraoperative Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) With Cisplatin to Treat Platinum-sensitive Recurrent Ovarian Cancer |
Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT01387399 |
| Cisplatin |
NCT02723864 |
Recruiting |
Phase 1 |
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
Neoplasms |
https://ClinicalTrials.gov/show/NCT02723864 |
| Cisplatin |
NCT00935961 |
Completed |
Phase 1 |
RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer |
HEAD & NECK Cancer |
https://ClinicalTrials.gov/show/NCT00935961 |
| Cisplatin |
NCT01869023 |
Unknown status |
Phase 2 |
Phase II Study of Six Hours Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma |
Advanced Malignant Pleural Mesothelioma |
https://ClinicalTrials.gov/show/NCT01869023 |
| Cisplatin |
NCT02182778 |
Completed |
Phase 3 |
GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer |
Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT02182778 |
| Cisplatin |
NCT01670500 |
Active, not recruiting |
Phase 2 |
Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa |
Breast Cancer |
https://ClinicalTrials.gov/show/NCT01670500 |
| Cisplatin |
NCT01444521 |
Completed |
Phase 2 |
Genotype-drive Study of Irinotecan-Cisplatin Combination for Advanced Gastric Cancer |
Gastric Cancer |
https://ClinicalTrials.gov/show/NCT01444521 |
| Cisplatin |
NCT04000906 |
Not yet recruiting |
Phase 1 |
PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis |
Peritoneal Carcinomatosis |
https://ClinicalTrials.gov/show/NCT04000906 |
| Cisplatin |
NCT01982448 |
Active, not recruiting |
Phase 2 |
Cisplatin vs Paclitaxel for Triple Neg |
Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT01982448 |
| Cisplatin |
NCT01336842 |
Completed |
Phase 1 |
Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors |
Solid Tumors|Non-Small Cell Lung Cancer (NSCLC) |
https://ClinicalTrials.gov/show/NCT01336842 |
| Cisplatin |
NCT01854203 |
Unknown status |
Phase 2|Phase 3 |
Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC |
Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT01854203 |
| Cisplatin |
NCT02254681 |
Terminated |
Phase 2 |
Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC |
Intrahepatic Cholangiocarcinoma |
https://ClinicalTrials.gov/show/NCT02254681 |
| Cisplatin |
NCT01096745 |
Terminated |
Phase 2 |
Randomized Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer |
Metastatic Biliary Tract Cancer|Locally Advanced Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT01096745 |
| Cisplatin |
NCT03275857 |
Recruiting |
Early Phase 1 |
Cisplatin in Castration Resistant Prostate Cancer |
Prostate Cancer |
https://ClinicalTrials.gov/show/NCT03275857 |
| Cisplatin |
NCT00808145 |
Withdrawn |
Phase 2 |
Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC) |
Hepatocellular Carcinoma |
https://ClinicalTrials.gov/show/NCT00808145 |
| Cisplatin |
NCT02207660 |
Completed |
N/A |
Cisplatin Plus One-Day 24-hour Infusion of High-Dose 5-Fluorouracil for Stage IVB, Recurrent or Metastatic Carcinoma of the Uterine Cervix |
Cervical Cancer |
https://ClinicalTrials.gov/show/NCT02207660 |
| Cisplatin |
NCT01872962 |
Active, not recruiting |
Phase 3 |
Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma |
Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT01872962 |
| Cisplatin |
NCT02351765 |
Completed |
Phase 1 |
ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers |
Biliary Tract Cancer|Gallbladder Cancer|Cholangiocarcinoma|Ampullary Cancer |
https://ClinicalTrials.gov/show/NCT02351765 |
| Cisplatin |
NCT01444547 |
Unknown status |
Phase 2 |
A Study on Predictive Value of ERCC1 in Esophageal Cancer Patients Treated With Paclitaxel and Cisplatin |
Esophageal Cancer |
https://ClinicalTrials.gov/show/NCT01444547 |
| Cisplatin |
NCT01285674 |
Unknown status |
Not Applicable |
Intratympanic Steroid Treatment For The Prevention Of Inner Ear Toxicity Associated With Systemic Treatment With Cisplatin. |
Cisplatin|Ototoxicity|Intratympanic Steroids |
https://ClinicalTrials.gov/show/NCT01285674 |
| Cisplatin |
NCT04192903 |
Not yet recruiting |
Phase 2 |
Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer |
Triple-negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT04192903 |
| Cisplatin |
NCT01801644 |
Completed |
Not Applicable |
Neoadjuvant Chemotherapy in Locally Advanced Bladder Cancer |
Bladder Cancer |
https://ClinicalTrials.gov/show/NCT01801644 |
| Cisplatin |
NCT02128906 |
Recruiting |
Phase 2 |
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design |
Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT02128906 |
| Cisplatin |
NCT01261728 |
Active, not recruiting |
Phase 2 |
Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma |
Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT01261728 |
| Cisplatin |
NCT00968435 |
Completed |
Phase 2 |
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma |
Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT00968435 |
| Cisplatin |
NCT03193853 |
Recruiting |
Phase 2 |
TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer |
Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03193853 |
